Intellia's Chief Scientific Officer elaborates on the news that the company successfully redosed patients with a CRISPR-based and LNP delivered therapy

blonca9
Jun 26, 2024
1 min read

Laura Sepp-Lorenzino shares details of this news and offers her opinion of the significance of it, and provides an overview of Intellia's development plans for its ATTR amyloidosis and AATD programs.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Intellia's Chief Scientific Officer elaborates on the news that the company successfully redosed patients with a CRISPR-based and LNP delivered therapy

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight